Date: 2014-07-25
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Infinity Pharmaceuticals (USA - MA)
Product: duvelisib
Action
mechanism: phosphoinositide 3-kinase (PI3K) inhibitor. Duvelisib is an oral inhibitor of Class I PI3K-delta,gamma. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity. The PI3K-delta,gamma isoforms are preferentially expressed in leukocytes (white blood cells), where they have distinct and mostly non-overlapping roles in immune cell development and function. Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to develop differentiated therapies for the treatment of hematologic malignancies.
Disease: follicular lymphoma
Therapeutic area: Cancer - Oncology
Country: Australia, France, Italy, Poland, Austria, Belgium, Canada, Czech Republic, Denmark, Germany, Hungary, Israel, New Zealand, Spain, UK, USA
Trial
details: This randomized, double-blind, placebo-controlled phase 3 will evaluate duvelisib (IPI-145) administered in combination with rituximab vs placebo in combination with rituximab in patients with previously treated CD20-positive follicular lymphoma who are not suitable candidates for chemotherapy. (NCT02204982)
Latest
news: * On July 25, 2014, a Phase 3 trial sponsored by Infinity Pharmaceuticals was published on the NIH website ClinicalTrials.gov for duvelisiban is currently recruiting participants.
